Log in

Cytokinetics Stock Price, News & Analysis (NASDAQ:CYTK)

$11.18
+0.41 (+3.81 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$10.86
Now: $11.18
$11.32
50-Day Range
$10.88
MA: $12.77
$14.50
52-Week Range
$5.75
Now: $11.18
$14.94
Volume314,815 shs
Average Volume476,608 shs
Market Capitalization$656.04 million
P/E RatioN/A
Dividend YieldN/A
Beta1.55
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.50 million
Book Value$0.47 per share

Profitability

Net Income$-106,290,000.00
Net Margins-308.73%

Miscellaneous

Employees130
Market Cap$656.04 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.


Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company had revenue of $7.14 million for the quarter, compared to the consensus estimate of $6.81 million. Cytokinetics had a negative return on equity of 575.21% and a negative net margin of 308.73%. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

6 equities research analysts have issued 1-year price targets for Cytokinetics' shares. Their predictions range from $16.00 to $26.00. On average, they anticipate Cytokinetics' stock price to reach $20.17 in the next year. This suggests a possible upside of 80.4% from the stock's current price. View Analyst Price Targets for Cytokinetics.

What is the consensus analysts' recommendation for Cytokinetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

Has Cytokinetics been receiving favorable news coverage?

Media coverage about CYTK stock has trended negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytokinetics earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Cytokinetics.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (amgn), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Geron (GERN), Inovio Pharmaceuticals (INO) and TG Therapeutics (TGTX).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%). Company insiders that own Cytokinetics stock include Caryn Gordon Mcdowell, Fady Ibraham Malik and Robert I Blum. View Institutional Ownership Trends for Cytokinetics.

Which institutional investors are buying Cytokinetics stock?

CYTK stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View Insider Buying and Selling for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $11.18.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $656.04 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.

What is Cytokinetics' official website?

The official website for Cytokinetics is http://www.cytokinetics.com/.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  624 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  883
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel